FindTrial
Sign In

Clinical trial of application of next generation sequencing (NGS) technology in hematological tumors

Clinical trial of application of next generation sequencing (NGS) technology in hematological tumors

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000032712
Enrollment
Unknown
Registered
2020-05-07
Start date
2020-05-06
Completion date
Unknown
Last updated
2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological tumors

Interventions

Case series:NGS testing

Sponsors

First Affiliated Hospital of Zhengzhou University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 100 Years

Inclusion criteria

Inclusion criteria: Patients who are tested by next generation sequencing in our hospital and diagnosed with hematological malignancies.

Exclusion criteria

Exclusion criteria: Non

Design outcomes

Secondary

MeasureTime frame
Overall Survival Rate;Event-free Survival;Complete remission rate;—

Primary

MeasureTime frame
Relapse-free survival;—

Countries

China

Contacts

Public ContactYan fang

First Affiliated Hospital of Zhengzhou University

fccliuyf1@zzu.edu.cn+86 13673665109

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026